Company news

Theriva Biologics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc.

November 2, 2026

Theriva Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

August 12, 2026

Theriva Biologics: Q2 Earnings Snapshot

August 11, 2026

Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

August 11, 2026

Theriva Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

August 7, 2026

Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

August 6, 2026

Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

July 7, 2026

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

May 5, 2026

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

April 17, 2026

Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma

March 23, 2026

Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

March 12, 2026

Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications

February 18, 2026

Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026

February 3, 2026

Theriva Biologics Announces Positive Scientific Advice from the European Medicines Agency on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma

December 30, 2025

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

December 29, 2025

Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results

November 12, 2025

Theriva Biologics Provides Response to Unusual Market Action

October 24, 2025

Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds

October 16, 2025

Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings

October 13, 2025

Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

October 6, 2025

Theriva Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

August 12, 2025

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

August 11, 2025

Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer

May 27, 2025

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

May 14, 2025

Theriva Biologics Announces Closing of $7.5 Million Public Offering

May 8, 2025

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

May 7, 2025

Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients

May 7, 2025

Calls

The 5 newest of 6 calls. Every call is listed under its year.

Decks

The 5 newest of 51 decks. Every deck is listed under its year.